{"denoms":[{"counts":[{"groupId":"BG000","value":"53"}],"units":"Participants"}],"groups":[{"description":"Cycle 1: Cyclophosphamide 300 mg/m\\^2 intravenous (IV) twice a day on Days 1-3. Mesna 600 mg/m\\^2 continuous IV Days 1-3. Doxil 25 mg/m\\^2 IV over 1 hour on Day 2. Vincristine 1.4 mg/m\\^2 IV on Days 4 and 11. Dexamethasone 40 mg Iv or oral on Days 1 - 4 and 11 - 14.\n\nCycle 2: Methotrexate 200 mg/m\\^2 over 2 hours on Day 1 and 800 mg/m\\^2 over 22 hours on day 1. Cytarabine 3 Gm/m\\^2 IV twice a day on Days 2 and 3.","id":"BG000","title":"HCVIDDOXIL Regimen"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"20","upperLimit":"72","value":"54"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"26"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"27"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"53"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}